A research priority
Oncology is the group’s main focus for pharmaceutical research. We put 50% of our budget toward our medical research. We are therefore the second French pharmaceutical company in terms of anti-cancer research.
Major medical needs
Our oncology research is based on areas where medical needs are greatest:
- Solid tumors, especially lung cancer, colon cancer, skin cancer, upper aerodigestive cancer, or urogenital cancer;
- Onco-hematology, including lymphoma, myeloma, and especially leukemia
Plant-based anti-cancer substances
More active and better tolerated natural molecules
In the early 1980s, Pierre Fabre Laboratories began its anti-cancer research by forming a partnership with the French National Center for Scientific Research to develop an anti-cancer agent using tropical periwinkle: Navelbine. Today Navelbine is one of the group’s top medicines and the first French anti-cancer agent to be approved in the United States for the treatment of lung cancer; it is one of the group’s key success stories. Javlor, a new-generation anti-cancer drug, is also the result of working with the French National Center for Scientific Research on tropical periwinkle.
Our R&D teams are currently working on the discovery and development of even more active and better tolerated natural molecules.
New courses of treatment centered on peptidic molecules
In February 2014, an inlicensing agreement was signed with Indienne Aurigen to develop a peptide whose antitumor activity will be evaluated by the Research and Development teams of Pierre Fabre Laboratories.
Internationally recognized expertise
The Center of Immunology Pierre Fabre (CIPF) at Saint-Julien-en-Genevois has internationally recognized scientific expertise in terms of the discovery and characterization of anti-cancerous monoclonal antibodies. The interest of monoclonal antibodies lies in their highly targeted mechanism of action: they bind only to specific receptors on certain types of tumor. When they come into contact with their target tumor, they are 100% effective. As well as being effective, they are better tolerated that chemotherapy drugs.
CIPF research teams have recently developed monoclonal antibodies that have aroused interest from the largest pharmaceutical groups:
- In 2010, a licensing agreement was signed with AbbVie to develop a second monoclonal antibody, which is also extremely promising in oncology.
- In 2015, a collaboration with Array BioPharma Inc. is announced to globally develop and commercialize late-stage novel oncology products : binimetinib and encorafenib.
This initial success has led us to work on the production of clinical batches of monoclonal antibodies to develop a candidate as far as Phase II.
Thanks to the new Antibodies Biotechnology Unit (ABU), we are the only pharmaceutical company in France to have research, development and clinical batch production facilities located at the same site.
Immunoconjugates are currently a growing therapeutic class for the treatment of cancer. These molecules, which combine a protein (of biological origin) with a cytotoxic agent (of synthetic or plant origin), make it possible to direct these active substances to the very heart of a tumorous cell, without affecting healthy cells. Our research teams have additional expertise in discovering, achieving and evaluating these molecules, combining the expertise of targeted biotherapeutics developed at Saint-Julien-en-Genevois, cytotoxic agents studied at the Toulouse Oncopole, and the chemical knowledge of teams in Toulouse.
Proximity to clinical practitioners
A large number of our cancer research teams are located at the Toulouse Oncopole. This campus, which is an essential facility of the CAPTOR project (Cancer Pharmacology of Toulouse and Region), known as the National Center of Excellence for cancer research, combines public and private research bodies, clinical practitioners, hospital staff, and patients. It enables close cooperation between researchers and care staff, and promotes better knowledge of diseases and their course. The tighter the links between research laboratories, clinical practitioners and patients, the quicker patients can benefit from the most recent and most effective forms of treatment.